Of the Field

OPT Congress 2026

PT Congress 2026 is the leading industry event for scientists, directors, and technology providers driving innovation across oligonucleotide, mRNA, and peptide therapeutics. Now in its 11th year, the event features expanded programming including a new Peptides & Emerging Drug Conjugates conference, with a focus on AI-enabled design, extrahepatic delivery, s…

Visit the official site

4Voices

0Underwriters

0Exhibitors

0On the bill · sessions

4Companies · in total

§I

The Voices

Programmed at OPT, in alphabetical order.

Brenda Bass, PhD

Distinguished Professor, Biochemistry, University of Utah · University of Utah

Debra Miller

Founder & CEO, CureDuchenne · CureDuchenne

Mano Manoharan, PhD

Distinguished Scientist & Senior Vice President, Alnylam Pharmaceuticals · Alnylam Pharmaceuticals

Timothy Yu, PhD

Associate Professor Pediatrics, Genetics & Genomics, Boston Children’s Hospital · Boston Children’s Hospital

Intermission

Part the Second · For the Buyer

An audience of 4 companies, parsed from the program.

“Four companies in attendance.”

The numbers below are derived from the speakers, sponsors, and exhibitors on this page — cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.

№ 01Fig. 01 — Composition of the House

0All threespeak · spons · exh

0Sponsoringsponsor only

0Exhibitingexhibitor only

4Speakingspeaker only

№ 02Fig. 02 — The Voices, by Seniority

50% of the speakers carry senior titles — C-suite, Founder, VP, or Director-level.

C-suite125%
VP-level125%
Other roles250%

Of 4 on the bill · classified by free-text title

№ 03Fig. 03 — The Heaviest in the Room

№ 04Fig. 04 — By Tier

Tiers were not disclosed for this convocation.